thrombogenics

Médias

ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US

Médias

ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

Médias

J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014

Médias

ThromboGenics' Founder Prof Desire Collen Receives Scrip Lifetime Achievement Award

Médias

ThromboGenics' Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada

Médias

Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole

Médias

JETREA® Selected for Single Technology Appraisal (STA) by the UK's National Institute for Health and Clinical Excellence (NICE)

Médias

ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin

Médias

ThromboGenics and BioInvent to Regain Full Rights to TB-403

Médias

ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402